These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
3. Hyperthermia after discontinuance of levodopa and bromocriptine therapy: impaired dopamine receptors a possible cause. Figà-Talamanca L; Gualandi C; Di Meo L; Di Battista G; Neri G; Lo Russo F Neurology; 1985 Feb; 35(2):258-61. PubMed ID: 3969217 [TBL] [Abstract][Full Text] [Related]
4. Neuroleptic-induced extrapyramidal symptoms with fever. Heterogeneity of the 'neuroleptic malignant syndrome'. Levinson DF; Simpson GM Arch Gen Psychiatry; 1986 Sep; 43(9):839-48. PubMed ID: 2875701 [TBL] [Abstract][Full Text] [Related]
5. Neuroleptic malignant syndrome: a pathogenetic role for dopamine receptor blockade? Henderson VW; Wooten GF Neurology; 1981 Feb; 31(2):132-7. PubMed ID: 6110195 [TBL] [Abstract][Full Text] [Related]
6. Heatstroke and hyperthermias. Amore M; Cerisoli M Ital J Neurol Sci; 1992 May; 13(4):337-41. PubMed ID: 1351046 [TBL] [Abstract][Full Text] [Related]
7. Pharmacologic effects on thermoregulation: mechanisms of drug-related heatstroke. Vassallo SU; Delaney KA J Toxicol Clin Toxicol; 1989; 27(4-5):199-224. PubMed ID: 2689657 [TBL] [Abstract][Full Text] [Related]
8. Multiple triggers for hyperthermic fatigue and exhaustion. Cheung SS; Sleivert GG Exerc Sport Sci Rev; 2004 Jul; 32(3):100-6. PubMed ID: 15243205 [TBL] [Abstract][Full Text] [Related]
9. A prostaglandin theory of neuroleptic malignant syndrome. Yeragani VK; Chaitin P Med Hypotheses; 1987 Oct; 24(2):143-9. PubMed ID: 2891019 [TBL] [Abstract][Full Text] [Related]
10. Drug-related heatstroke. Clark WG; Lipton JM Pharmacol Ther; 1984; 26(3):345-88. PubMed ID: 6152566 [No Abstract] [Full Text] [Related]
11. Neuroleptic malignant syndrome in Parkinson's disease after withdrawal or alteration of dopaminergic therapy. Keyser DL; Rodnitzky RL Arch Intern Med; 1991 Apr; 151(4):794-6. PubMed ID: 1672810 [TBL] [Abstract][Full Text] [Related]
12. Brain neurotransmitter changes in three patients who had a fatal hyperthermia syndrome. Kish SJ; Kleinert R; Minauf M; Gilbert J; Walter GF; Slimovitch C; Maurer E; Rezvani Y; Myers R; Hornykiewicz O Am J Psychiatry; 1990 Oct; 147(10):1358-63. PubMed ID: 2133042 [TBL] [Abstract][Full Text] [Related]
13. [Clinical picture and course of the neuroleptic malignant syndrome (acute febrile neuroleptic encephalopathy)]. Avrutskiĭ GIa; Raĭskiĭ VA; Tsygankov BD Zh Nevropatol Psikhiatr Im S S Korsakova; 1987; 87(9):1391-6. PubMed ID: 3425085 [TBL] [Abstract][Full Text] [Related]
17. Toxin-induced hyperthermic syndromes. Rusyniak DE; Sprague JE Med Clin North Am; 2005 Nov; 89(6):1277-96. PubMed ID: 16227063 [TBL] [Abstract][Full Text] [Related]
18. Effects of exercise in the heat on predisposition to heatstroke. Hubbard RW Med Sci Sports; 1979; 11(1):66-71. PubMed ID: 384135 [TBL] [Abstract][Full Text] [Related]
19. Dantrolene--a new therapeutic approach to the neuroleptic malignant syndrome. Bismuth C; de Rohan-Chabot P; Goulon M; Raphael JC Acta Neurol Scand Suppl; 1984; 100():193-8. PubMed ID: 6148831 [TBL] [Abstract][Full Text] [Related]
20. Summer heat illnesses. Conditions that range from mild to fatal. Sterner S Postgrad Med; 1990 Jun; 87(8):67-70, 73. PubMed ID: 2345717 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]